Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 11, 2026
Ferrari (RACE) Shares Climb +8% on Strong Q2 Earnings and Raised Guidance

Ferrari (RACE) Shares Climb +8% on Strong Q2 Earnings and Raised Guidance

Key Takeaways

  • Ferrari shares have climbed approximately 8% over the past 30 days, driven by robust Q2 2026 earnings that exceeded expectations and an upward revision to full-year guidance.
  • The company reported Q2 net revenues of €1.94 billion, up 8% year-over-year, with adjusted EBITDA of €755 million and an EBITDA margin of 39%.
  • Ferrari raised its FY2026 outlook, now projecting at least €9.68 in adjusted diluted EPS and approximately €7.6 billion in revenue, reflecting strong personalization trends and a more favorable FX environment.
  • The order book extends through the entirety of 2027, with high-demand models including the 296 Speciale and Dodici Cilindri families already sold out for their production runs.
  • Wall Street maintains a broadly constructive stance, with a consensus "Moderate Buy" rating and an average 12-month price target above $450.

Ferrari's Recent Stock Performance

Ferrari N.V. shares closed at $406.77 on August 10, 2026, capping a month of steady recovery that saw the stock gain roughly 8% from mid-July levels near $376. The luxury automaker has outperformed broader consumer discretionary benchmarks during this stretch, buoyed by a well-received earnings report and sustained investor confidence in its pricing power. Trading volumes surged around the late-July earnings release, with the stock briefly touching $412.26 before settling into a consolidation range. The stock remains approximately 20% below its 52-week high near $505, reflecting a lingering valuation reset that multiple analysts have characterized as an opportunity rather than a fundamental concern.

Ferrari's Business Model and Competitive Position

Ferrari N.V., headquartered in Maranello, Italy, is one of the world's most recognizable luxury automotive brands. The company designs, engineers, and manufactures high-performance sports cars that command average selling prices well above €500,000. Unlike mass-market automakers, Ferrari deliberately constrains production volumes to preserve exclusivity — shipping just 13,640 units in 2025. The business generates approximately 84% of its revenue from car and spare parts sales, with the remainder derived from sponsorship agreements, brand licensing, and Formula 1 commercial activities. Ferrari's competitive moat rests on a combination of iconic brand equity, a multi-year order backlog, exceptional pricing authority, and a client base dominated by repeat buyers. The company's strategy of layering limited-edition hypercars (such as the F80) and high-margin personalization programs atop its core range has consistently produced industry-leading margins — the EBIT margin reached 31.2% in Q2 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Developments Supporting RACE

The most significant catalyst over the past 30 days was Ferrari's Q2 2026 earnings release on July 30. The company posted net revenues of €1.94 billion (up 8% year-over-year, or 11% at constant currency) and adjusted diluted EPS of €2.62, surpassing analyst consensus estimates. Perhaps more importantly, management raised full-year guidance across nearly every key metric: revenue guidance climbed to approximately €7.6 billion from €7.5 billion, adjusted EBITDA to at least €2.97 billion from €2.93 billion, and adjusted diluted EPS to at least €9.68 from €9.45. CEO Benedetto Vigna attributed the upgraded outlook to stronger-than-expected personalization adoption, which now accounts for over 20% of car and spare parts revenue. Analysts responded favorably — Evercore ISI raised its price target to $485, UBS reiterated its Buy rating with a $490 target, and Morgan Stanley maintained its Overweight stance at $439. On the product front, the company unveiled the 12Cilindri Manuale in Q3, adding a gated-manual variant that has generated significant enthusiast interest. The Ferrari Luce, the brand's first fully electric vehicle unveiled in May, has reportedly reached its 2026 sales target within two months, though some market observers remain cautious about long-term EV demand within Ferrari's traditional client base.

2026 Outlook and Key Factors to Monitor

Looking ahead through the remainder of 2026, several factors will shape Ferrari's investment narrative. The company's next earnings report, estimated for early November, will be closely scrutinized for confirmation that personalization momentum and product mix strength are sustainable into the second half. Currency exposure remains a wildcard — CFO Antonio Picca Piccon noted on the Q2 call that only about 8% of 2027 FX exposure is hedged, leaving results vulnerable to USD/EUR fluctuations. The gradual ramp-up of Luce deliveries beginning in Q4 2026 represents both an opportunity and an overhang; successful execution could expand Ferrari's addressable market, while any misstep might pressure the stock's premium valuation. Analysts will also monitor the pace of D&A normalization as the model changeover cycle progresses, which could compress margins in H2. On the competitive front, Ferrari's deliberate volume restraint and scarcity-driven strategy continue to differentiate it from peers such as Tesla (TSLA) and BMW (BMWYY), though the broader luxury auto segment faces ongoing tariff uncertainty. With an order book extending through 2027 and a consensus analyst price target implying double-digit upside, Ferrari enters the second half of 2026 with considerable operational momentum, even as macroeconomic crosscurrents warrant continued vigilance.

Integrating Tickeron’s AI Tools Into My Process

In my view, AI-driven resources add useful context when evaluating names like Ferrari. I regularly review Tickeron’s Trending AI Robots to see how automated strategies are performing across sectors, including luxury autos. The platform highlights top bots with transparent metrics on win rates and trade history, helping me cross-check my own analysis without replacing it.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RACE

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


RACE's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for RACE turned positive on July 29, 2026. Looking at past instances where RACE's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on RACE as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for RACE moved above the 200-day moving average on July 31, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RACE advanced for three days, in of 322 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 263 cases where RACE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RACE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RACE broke above its upper Bollinger Band on July 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RACE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.920) is normal, around the industry mean (9.154). P/E Ratio (37.933) is within average values for comparable stocks, (542.467). Projected Growth (PEG Ratio) (4.062) is also within normal values, averaging (2.910). Dividend Yield (0.010) settles around the average of (0.037) among similar stocks. P/S Ratio (8.418) is also within normal values, averaging (11.674).

Notable companies

The most notable companies in this group are Tesla (NASDAQ:TSLA), General Motors Company (NYSE:GM), Ford Motor Company (NYSE:F), NIO Inc. (NYSE:NIO).

Industry description

Automobiles continue to be arguably the most popular form of passenger travel in the U.S., and major automobile makers have revenues and market capitalizations running into multi-billions. In recent years, the industry has been experiencing some path-breaking innovations like electric vehicles and self-driving technology. While there are long-standing companies like General Motors, Ford, and Toyota Motors operating in this space, there are also emerging/rapidly growing players like Tesla – which has had a major role in the growing popularity of the electric vehicle market. With technological advancements taking steam in the auto space, we’ve also witnessed collaborations (or talks of potential partnerships) of carmakers with tech behemoths like Google’s subsidiary, Waymo.

Market Cap

The average market capitalization across the Motor Vehicles Industry is 62.43B. The market cap for tickers in the group ranges from 3.72K to 1.31T. TSLA holds the highest valuation in this group at 1.31T. The lowest valued company is ZAPPF at 3.72K.

High and low price notable news

The average weekly price growth across all stocks in the Motor Vehicles Industry was -4%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -20%. SEV experienced the highest price growth at 16%, while LVWR experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Motor Vehicles Industry was -22%. For the same stocks of the Industry, the average monthly volume growth was -31% and the average quarterly volume growth was -59%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 58
Price Growth Rating: 62
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: 10 (-100 ... +100)
View a ticker or compare two or three
RACE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

an operator of an automobile company, which engages in the designing, engineering, producing and selling of sports cars

Industry MotorVehicles

Profile
Details
Industry
Motor Vehicles
Address
Via Abetone Inferiore n. 4
Phone
+39 536949111
Employees
4988
Web
https://www.ferrari.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Ferrari (RACE) Shares Climb +8% on Strong Q2 Earnings and Raised Guidance